Hydroxychloroquine, COVID‐19 and diabetes. Why it is a different story
- 27 June 2020
- journal article
- editorial
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 37 (2), e3379
- https://doi.org/10.1002/dmrr.3379
Abstract
Click on the article title to read more.Keywords
This publication has 16 references indexed in Scilit:
- Addressing the spatial disconnect between national-scale total maximum daily loads and localized land management decisionsJournal of Environmental Quality, 2020
- New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?International Journal of Antimicrobial Agents, 2020
- Hyperglycemia, hydroxychloroquine, and the COVID‐19 pandemicJournal of Medical Virology, 2020
- Chloroquine or hydroxychloroquine for prophylaxis of COVID-19The Lancet Infectious Diseases, 2020
- Diabetes is a risk factor for the progression and prognosis of COVID‐19Diabetes/Metabolism Research and Reviews, 2020
- Potential Effect of Hydroxychloroquine in Diabetes Mellitus: A Systematic Review on Preclinical and Clinical Trial StudiesJournal of Diabetes Research, 2020
- Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individualsArthritis Research & Therapy, 2012
- Hydroxychloroquine in Decompensated, Treatment-Refractory Noninsulin-Dependent Diabetes MellitusAnnals of Internal Medicine, 1990
- Effect of chloroquine on insulin and glucose homoeostasis in normal subjects and patients with non-insulin-dependent diabetes mellitus.BMJ, 1987